| Registry | NCT04417543 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional; randomized, parallel, masking: double, treatment |
| Enrollment | 100 (Actual) |
| Sponsor | Assiut University (Other) |
| Conditions | Epilepsy |
| Interventions | Memantine Hydrochloride, Placebo (Drug) |
| Dates | start 2018-10-01, primary completion 2019-10-01, completion 2020-01-15, first posted 2020-06-04, last updated 2020-06-04 |
| Locations | 1 site in Egypt |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Epilepsy All trials of Memantine Hydrochloride All trials of Placebo
Evaluate the efficacy of memantine on improving the cognitive impairment in patient with epilepsy
Epilepsy is a complex disorder, which involves much more than seizures, encompassing a range of associated comorbid health conditions that can have significant health and quality-of-life implications. Of these comorbidities, cognitive impairment is one of the most common and distressing aspects of epilepsy.
Excito-toxicity, mediated by glutamate acting on N-methyl-D-aspartate (NMDA) receptors in the hippocampus, can cause memory dysfunction in epilepsy .
Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor . It also has antioxidant property and increases production of brain derived neurotropic factor (BDNF)
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Memantine hydrochloride group | Active comparator | Drug: Memantine Hydrochloride | included 50 patients who received memantine |
| Placebo group | Placebo comparator | Drug: Placebo | included 50 patients who received placebo |
Sex: All, ages: 18 Years to 55 Years
Inclusion Criteria: * Patients with idiopathic epilepsy. * Normal brain imaging (CT brain). * Patients on anti epileptic drugs more than 6 months. * No more than two fits per month. * Score of Mini mental state examination (10-24), mild and moderate cognitive impairment. * No other medical disorders. Exclusion Criteria: * Progressive neurological diseases. * Abnormal brain imaging (CT brain). * More than two fits per month. * Patients with severe cognitive impairment, score of MMSE less than10. * Patients with severe medical disorders
| Facility | City | Country | Status |
|---|---|---|---|
| Salma Mohmed Fahmy | Asyut | Egypt |